Investigation ongoing – statement to be updated as more information is available FDA alerts patients and health care professionals to Sandoz’s losartan potassium and hydrochlorothiazide recall of one lot due to NDEA Update [11/9/2018] FDA is alerting patients and health care professionals to Sandoz’s voluntary recall of one lot – JB8912 – of losartan potassium and hydrochlorothiazide 100mg/25mg …
First Valsartan, Now Losartan Recall: Here’s What Patients Need To KnowRead More